Affilin® Technology

Scil Proteins focuses on the development of biotherapeutics applying its proprietary Affilin® technology for its own pipeline as well as in collaboration with pharmaceutical partners. Affilin® molecules are based on the human Ubiquitin scaffold and engineered to generate de-novo binding affinity towards disease-relevant targets. The platform allows the generation of agonistic or antagonistic binding molecules, their fusion to effector molecules or multispecific designs. Thus, Affilin® molecules present an attractive alternative or complement to conventional antibody formats, broadening the application space of biotherapeutics.

Dr. Ulrich Haupts, CSO

“The high affinity and specificity combined with the possibility of modular design make our Affilin® molecules highly attractive as biopharmaceutical drugs.”


Scil Proteins GmbH’s website is currently under construction. You will find our new homepage shortly at


For information with regard to the Affilin® drug discovery and protein engineering services please contact us here.


Scil Proteins Production GmbH joined Wacker Biotech GmbH with effective date 1.1.2014. For information please click here.

If you need information regarding GMP manufacturing and Process Development Services please contact us.

For information related to Wacker Biotech please visit